ストックスクリーナーアプリを入手
2.63
1.50%
-0.04
アフターアワーズ：
2.84
0.21
+7.98%
前日終値:
$2.67
開ける：
$2.67
24時間の取引高:
22,752
Relative Volume:
0.02
時価総額：
$3.33M
収益：
-
当期純損益:
$-16.28M
株価収益率:
-4.0462
EPS:
-0.65
ネットキャッシュフロー:
$-13.75M
1週間 パフォーマンス:
-0.75%
1か月 パフォーマンス:
-17.55%
6か月 パフォーマンス:
-46.35%
1年 パフォーマンス:
-53.04%
1日の値動き範囲:
$2.5775
$2.81
1週間の範囲:
$2.37
$2.81
52週間の値動き範囲:
$2.37
$9.40
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
KTTA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
2.63 | 3.33M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pasithea Therapeutics Corp (KTTA) 最新ニュース
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) and MusclePharm (OTCMKTS:MSLP) - Defense World
KTTA stock touches 52-week low at $2.72 amid market challenges - Investing.com Nigeria
KTTA stock touches 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $2.87 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - The Manila Times
Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan
Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% – Still a Buy? - Defense World
KTTA stock touches 52-week low at $3.19 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $3.19 amid market challenges - Investing.com UK
ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeuti - GuruFocus.com
KTTA stock touches 52-week low at $3.4 amid market challenges - Investing.com Australia
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA) - The Wall Street Transcript
KTTA stock touches 52-week low at $3.6 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $3.6 amid market challenges By Investing.com - Investing.com South Africa
pasithea therapeutics corp Earnings dates - RTTNews
(KTTA) Investment Analysis - Stock Traders Daily
Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com
Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News
PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal
Pasithea Therapeutics drops 19% on $5M private placement - MSN
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal
Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks
Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR
Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices
Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire
Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga
Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance
Why XPeng Stock Spiked Higher Today - Yahoo! Voices
Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL
KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News
Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga
English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices
Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch
Pasithea reports positive early data on cancer drug PAS-004 - Investing.com India
Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices
Pasithea Therapeutics (KTTA) Sees Strong Pre-Market Gains - Stocks Telegraph
Pasithea Therapeutics rises on positive early-stage data from cancer drug - XM
Pasithea Therapeutics : Investor Presentation - Marketscreener.com
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), And Preliminary Efficacy Data From Its Phase 1 Clinical T... - MENAFN.COM
Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004 - StreetInsider.com
Pasithea Therapeutics Announces Positive Initial Safety, - GlobeNewswire
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - StockTitan
Factbox-OpenAI key personnel changes - Yahoo! Voices
Pasithea Therapeutics Corp (KTTA) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):